Engineering oncolytic vaccinia virus to redirect macrophages to tumor cells-Reference-Cited by-同舟云学术

Engineering oncolytic vaccinia virus to redirect macrophages to tumor cells

Published:2020-07-12 Issue:2 Volume:4 Page:
ISSN:2573-8461
Container-title:ADVANCES IN CELL AND GENE THERAPY
language:en
Short-container-title:Adv Cell Gene Ther

Author:

Cao Felicia¹²³,Nguyen Phuong¹⁴⁵⁶,Hong Bangxing¹,DeRenzo Christopher¹⁴⁵,Rainusso Nino C.⁴⁵,Rodriguez Cruz Tania¹,Wu Meng‐Fen⁷,Liu Hao⁸,Song Xiao‐Tong¹,Suzuki Masataka¹,Wang Lisa L.⁴⁵,Yustein Jason T.⁴⁵,Gottschalk Stephen¹⁴⁵⁶^ORCID

Affiliation:

1. Center for Cell and Gene Therapy Texas Children’s HospitalHouston Methodist HospitalBaylor College of Medicine Houston TX USA

2. Interdepartmental Program in Translational Biology and Molecular Medicine Baylor College of Medicine Houston TX USA

3. Medical Scientist Training Program Baylor College of Medicine Houston TX USA

4. Texas Children’s Cancer and Hematology CentersTexas Children’s HospitalBaylor College of Medicine Houston TX USA

5. Department of Pediatrics Baylor College of Medicine Houston TX USA

6. Department of Bone Marrow Transplantation and Cellular Therapy St. Jude Children’s Research Hospital Memphis TN USA

7. Biostatistics Shared Resource Dan L Duncan Cancer Center Baylor College of Medicine Houston TX USA

8. Department of Biostatistics Indiana University School of Medicine Indianapolis IN USA

Publisher

Hindawi Limited

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/acg2.99

Reference59 articles.

1. Oncolytic Virotherapy: A Contest between Apples and Oranges

2. Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer

3. Oncolytic virotherapy

4. Phase I Trial of Intravenous Oncolytic Vaccinia Virus (GL-ONC1) with Cisplatin and Radiotherapy in Patients with Locoregionally Advanced Head and Neck Carcinoma

5. Open‐label phase II study evaluating the efficacy and safety of Talimogene Laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced, unresectable melanoma;Chesney J;J Clin Oncol.,2017

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Oncolytic virus and tumor-associated macrophage interactions in cancer immunotherapy;Clinical and Experimental Medicine;2024-08-28

2. Tumor associated macrophages as key contributors and targets in current and future therapies for melanoma;Expert Review of Clinical Immunology;2024-03-27

3. Immune landscape and response to oncolytic virus-based immunotherapy;Frontiers of Medicine;2024-03-08

4. Improving the therapeutic efficacy of oncolytic viruses for cancer: targeting macrophages;Journal of Translational Medicine;2023-11-22

5. The CD47-SIRPα axis is a promising target for cancer immunotherapies;International Immunopharmacology;2023-07